Today’s immunotherapeutics market consists of over 20 approved monoclonal antibodies some of which have market sizes of over $10B.  The market size is predicted to reach $47B by 2012.  There are over 500 monoclonals in development by 200 companies and over 80 in clinical trials.

This level of interest in antibody-based immunotherapy confirms the potential of next generation product classes to replace conventional monoclonals.  Origen believes that polyclonal antibodies will be a major factor in the next generation of immunotherapeutics.